Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition by Wilson H Miller, Meagan-Helen Henderson Berg, Sonia Victoria del Rincón

Get full text

Two Cases of Durable and Deep Responses to Immune Checkpoint Inhibition-Refractory Metastatic Melanoma after Addition of Camu Camu Prebiotic by Steph A. Pang, Arielle Elkrief, Mariana Pilon Capella, Wilson H. Miller

Get full text

The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma by Sathyen A. Prabhu, Omar Moussa, Wilson H. Miller, Sonia V. del Rincón

Get full text

RIG-I is required for the inhibition of measles virus by retinoids. by Kaitlin J Soye, Claire Trottier, Chris D Richardson, Brian J Ward, Wilson H Miller

Get full text

The impact of lag time to cancer diagnosis and treatment on clinical outcomes prior to the COVID-19 pandemic: A scoping review of systematic reviews and meta-analyses by Parker Tope, Eliya Farah, Rami Ali, Mariam El-Zein, Wilson H Miller, Eduardo L Franco

Get full text

Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. by Luca A Petruccelli, Daphné Dupéré-Richer, Filippa Pettersson, Hélène Retrouvey, Sophia Skoulikas, Wilson H Miller

Get full text

NPM and BRG1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia by Jessica N. Nichol, Matthew D. Galbraith, Claudia L. Kleinman, Joaquín M. Espinosa, Wilson H. Miller Jr.

Get full text

Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer. by Cynthia Guilbert, Matthew G Annis, Zhifeng Dong, Peter M Siegel, Wilson H Miller, Koren K Mann

Get full text

Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report by Wilson H Miller, Khashayar Esfahani, Meagan-Helen Henderson Berg, Hanieh Zargham, Robin Billick, Kevin Pehr, Margaret Redpath, Osama Roshdy

High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial. by L John Hoffer, Line Robitaille, Robert Zakarian, David Melnychuk, Petr Kavan, Jason Agulnik, Victor Cohen, David Small, Wilson H Miller

Get full text

Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer. by Cristiano Ferrario, Ivan Strepponi, Khashayar Esfahani, Helen Charamis, Adrian Langleben, Emanuela Scarpi, Oriana Nanni, Wilson H Miller, Lawrence C Panasci

Get full text

Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies by Gerald eBatist, Gerald eBatist, Gerald eBatist, Jian Hui eWu, Jian Hui eWu, Jian Hui eWu, Alan eSpatz, Alan eSpatz, Alan eSpatz, Alan eSpatz, Wilson H Miller, Wilson H Miller, Wilson H Miller, Eftihia eCocolakis, Caroline eRousseau, Zuanel eDiaz, Cristiano eFerrario, Cristiano eFerrario, Cristiano eFerrario, Mark eBasik, Mark eBasik, Mark eBasik, Mark eBasik

Get full text

Optimized protocol for immunophenotyping of melanoma and tumor-bearing skin from mouse by Sai Sakktee Krisna, Christophe Goncalves, Natascha Gagnon, Fan Huang, Dany Plourde, Wilson H. Miller, Jr., Jörg H. Fritz, Sonia V. del Rincon

Get full text

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements by Alia Thawer, Wilson H. Miller, Nancy Gregorio, Joël Claveau, Sudha Rajagopal, Kerry J. Savage, Xinni Song, Teresa M. Petrella, on behalf of the Canadian Working Group

Get full text

A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E by Sarit Assouline, Biljana Culjkovic-Kraljacic, Julie Bergeron, Stephen Caplan, Eftihia Cocolakis, Caroline Lambert, Cara J. Lau, Hiba Ahmad Zahreddine, Wilson H. Miller, Katherine L. B. Borden

Get full text

The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity by Hiba Ahmad Zahreddine, Biljana Culjkovic-Kraljacic, Audrey Emond, Filippa Pettersson, Ronald Midura, Mark Lauer, Sonia Del Rincon, Valbona Cali, Sarit Assouline, Wilson H Miller, Vincent Hascall, Katherine LB Borden

Get full text

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation by Khashayar Esfahani, Tho-Alfakar Al-Aubodah, Pamela Thebault, Réjean Lapointe, Marie Hudson, Nathalie A. Johnson, Dana Baran, Najwa Bhulaiga, Tomoko Takano, Jean-François Cailhier, Ciriaco A. Piccirillo, Wilson H. Miller

Get full text

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy by Giuseppe Procopio, Prabhu Bhagavatheeswaran, Bernard Escudier, Chung-Han Lee, Shruti Shally Saggi, Suresh Nair, Ruth Perets, Michael A Carducci, Vincent Castonguay, Edmund Folefac, Sebastien J. Hotte, Wilson H Miller, Heshani Desilva

Get full text

Tunable PhenoCycler imaging of the murine pre-clinical tumour microenvironments by Madelyn J. Abraham, Christophe Goncalves, Paige McCallum, Vrinda Gupta, Samuel E. J. Preston, Fan Huang, Hsiang Chou, Natascha Gagnon, Nathalie A. Johnson, Wilson H. Miller, Koren K. Mann, Sonia V. del Rincon

Get full text

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma by Antoni Ribas, Alain Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael Gordon, Leonel Hernandez-Aya, Donald Lawrence, Jose Lutzky, Wilson H. Miller, Katie M. Campbell, Bruno Delafont, Shannon Marshall, Nancy Mueller, Caroline Robert

Get full text